Lecturer Muhammad Nadhim Bahjat and Zainab Nizar Jawad / College of Education for Pure Sciences / University of Kerbala have obtained a patent from Central Organization for Standardization and Quality Control to enable them to manufacture a new drug compound and use it to treat and inhibit rapid spread of lung cancer cells.
The patent includes measuring the rate of release of innovative treatment at different acid levels of buffer solutions in a laboratory setting.
The treatment provides success in releasing the drug from new prepared nanocomposite in stomach at a very small percentage and in intestine at a very large percentage.
The patent is able to study the nature of interactions between the drug loaded on chitosan and protein that causes growth and spread of lung cancer line (A549). It also identifies amino acids that make up the protein that attract with the drug.
The patent concludes that nano-drug composite (mefenamic acid drug loaded on nano-chitosan) is a suitable and promising strategy for developing an effective drug delivery system for clinical application against lung cancers.
